Cytokines and microRNAs in SARS-CoV-2: What do we know?

(2022) Cytokines and microRNAs in SARS-CoV-2: What do we know? MOLECULAR THERAPY-NUCLEIC ACIDS. pp. 219-242. ISSN 2162-2531 J9 - MOL THER-NUCL ACIDS

Full text not available from this repository.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19.

Item Type: Article
Keywords: RESPIRATORY SYNDROME CORONAVIRUS NECROSIS-FACTOR-ALPHA NF-KAPPA-B I-INTERFERON CHEMOKINE RECEPTORS GENE-EXPRESSION IFN-GAMMA INFLAMMATORY CYTOKINES IMMUNODEFICIENCY-VIRUS SIGNAL-TRANSDUCTION
Page Range: pp. 219-242
Journal or Publication Title: MOLECULAR THERAPY-NUCLEIC ACIDS
Journal Index: ISI
Volume: 29
Identification Number: https://doi.org/10.1016/j.omtn.2022.06.017
ISSN: 2162-2531 J9 - MOL THER-NUCL ACIDS
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/16122

Actions (login required)

View Item View Item